was approved a few years ago for treating some types of blood cancers such as leukemia in humans, but O'Halloran thinks the arsenic trioxide
nanobins can be used against breast cancer and other solid tumors.
This study investigated the sealing ability of a novel sealer based on MTA; mineral trioxide
aggregate sealer (MTAS), reported that MTAS has a sealing ability similar to zinc oxide eugenol sealer (Pulp Canal Sealer (PCS)).
Differentiation syndrome: Differentiation syndrome is a complex set of symptoms that are associated with ATRA or arsenic trioxide
sol was produced by sol-gel method and by solving tungsten wire in oxygenated water.
Industrial production of sulfuric acid requires that sulfur dioxide be further oxidized to give sulfur trioxide
, which produces sulfuric acid when dissolved in water.
Originally, as mentioned above, traditional chemotherapy was then used, but it was shown that arsenic trioxide
The study will evaluate Tamibarotene in patients with relapsed or refractory APL following treatment with ATRA (all-trans retinoic acid) and arsenic trioxide
The study showed that adults with previously untreated APL who had standard chemotherapy to induce remission of their disease and then received injectable chemotherapy drug arsenic trioxide
to maintain remission lived longer than those who received only standard chemotherapy.
The objective therefore, was (1) to evaluate PFT-[alpha] for differential cellular protection in response to arsenic trioxide
and cadmium chloride exposure of normal and neoplastic cells, and (2) to evaluate the transcriptional activation of p53 and p53-responsive genes in rat liver cells and HepG2 carcinoma cell line.
CHAPTER 5 OF TM 1-1500-3440-23 SPECIFIES A MIXTURE OF ONE GALLON OF CHROMIUM TRIOXIDE
AND CALCIUM SULFATE.
is known for its use in the treatment of acute promyelocytic leukemia in patients who are unresponsive to, or have relapsed from, certain chemotherapy agents.
can cause QT prolongation (which can lead to torsade de pointes) and complete atrioventricular block.
A refinery in Canada failed to inform the proper officials after it released five tons of sulphur trioxide
is already used on patients who suffer a relapse after initial treatment for acute promyeloctytic leukaemia (APL).
The European Commission designated the medicinal product arsenic trioxide
an orphan drug in October 2000.